The University of Southampton
University of Southampton Institutional Repository

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m2/day for a maximum of 24 weeks) ±MMC (7 mg/m2 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.
unknown primary, carcinoma, 5-fluorouracil, randomised
0959-8049
1121-1128
Assersohn, L.
a9e1bdf4-44e4-4e9a-85ca-2023b704c19b
Norman, A.R.
9d5636c7-72da-4a29-80f1-e3d79c501639
Cunningham, D.
02b4fd3a-f452-4419-96a7-f98f609f098d
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Seymour, M.
79cb91bf-b3e6-4222-82cf-c0072be29613
Hickish, T.
d17bf903-3f13-4b46-9389-f0f458083442
Massey, A.
08a6fb9c-7d43-41dc-8e32-5b55bba229a4
Prior, Y.
124b2e90-4a34-4a09-89b2-6e044de29772
Hill, M.E.
7821ba06-51cb-4960-a4ab-a6f5c0f61bd9
Assersohn, L.
a9e1bdf4-44e4-4e9a-85ca-2023b704c19b
Norman, A.R.
9d5636c7-72da-4a29-80f1-e3d79c501639
Cunningham, D.
02b4fd3a-f452-4419-96a7-f98f609f098d
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Seymour, M.
79cb91bf-b3e6-4222-82cf-c0072be29613
Hickish, T.
d17bf903-3f13-4b46-9389-f0f458083442
Massey, A.
08a6fb9c-7d43-41dc-8e32-5b55bba229a4
Prior, Y.
124b2e90-4a34-4a09-89b2-6e044de29772
Hill, M.E.
7821ba06-51cb-4960-a4ab-a6f5c0f61bd9

Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E. (2003) A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer, 39 (8), 1121-1128. (doi:10.1016/S0959-8049(03)00150-3).

Record type: Article

Abstract

No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m2/day for a maximum of 24 weeks) ±MMC (7 mg/m2 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.

Full text not available from this repository.

More information

Published date: 2003
Keywords: unknown primary, carcinoma, 5-fluorouracil, randomised

Identifiers

Local EPrints ID: 26206
URI: https://eprints.soton.ac.uk/id/eprint/26206
ISSN: 0959-8049
PURE UUID: d8c8ff80-5f09-4e17-89f5-100ecf3c4a3f

Catalogue record

Date deposited: 21 Apr 2006
Last modified: 17 Jul 2017 16:08

Export record

Altmetrics

Contributors

Author: L. Assersohn
Author: A.R. Norman
Author: D. Cunningham
Author: T. Iveson
Author: M. Seymour
Author: T. Hickish
Author: A. Massey
Author: Y. Prior
Author: M.E. Hill

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×